Zylox-Tonbridge Medical Technology Co., Ltd. (ZYLOXTB) repurchased 48,000 H shares on 16 April 2026 via the Hong Kong Stock Exchange, paying HKD 23.60–24.24 per share, for an aggregate consideration of HKD 1.15 million.

The transaction represents 0.0143% of the company’s outstanding shares (excluding treasury stock) prior to the buyback. All repurchased shares are being held as treasury shares, lifting the treasury balance to 8.31 million.

Following the buyback, Zylox-Tonbridge’s issued share capital (excluding treasury shares) stands at 328.05 million, while the total issued share count remains unchanged at 336.35 million.

The purchase was executed under the share-repurchase mandate approved on 30 May 2025, which authorises up to 31.96 million shares. Cumulative repurchases under this mandate now total 5.49 million shares, equivalent to 1.68% of the company’s issued share base when the mandate was granted.

Under Hong Kong listing rules, Zylox-Tonbridge is restricted from issuing, selling, or transferring shares for 30 days after the repurchase, setting the moratorium period to 16 May 2026.